Ionel I. Mangalagiu

Prof. Ionel I. Mangalagiu

Alexandru Ioan Cuza University, Iaşi, Romania
orcid

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 January 2023 in Molecules
Verified
Journal Article
Open access
PDF file
ALAndrei Lobiuc
Andrei Lobiuc
NPNaomi-Eunicia Paval
Naomi-Eunicia Paval
Ionel I. MangalagiuIonel I. Mangalagiu
Ionel I. Mangalagiu
Roxana Gheorghita (Puscaselu)Roxana Gheorghita (Puscaselu)
Roxana Gheorghita (Puscaselu)
GTGabriel-Ciprian Teliban
Gabriel-Ciprian Teliban
Vasile StoleruVasile Stoleru
Vasile Stoleru
With incidence of antimicrobial resistance rising globally, there is a continuous need for development of new antimicrobial molecules. Phenolic compounds having a versatile scaffold that allows for a broad range of chemical additions; they also exhibit potent antimicrobial activities which can be enhanced significantly through functionalization. Synthetic routes such as esterification, phosphorylation, hydroxylation or enzymatic conjugation may increase the antimicrobial activity of compounds and reduce minimal concentrations needed. With potent action mechanisms interfering with bacterial cell wall synthesis, DNA replication or enzyme production, phenolics can target multiple sites in bacteria, leading to a much higher sensitivity of cells towards these natural compounds. The current review summarizes some of the most important knowledge on functionalization of natural phenolic compounds and the effects on their antimicrobial activity.

1 November 2010 in Colloids and Surfaces A: Physicochemical and Engineering Aspects
Verified
Journal Article
Closed access
DZDaniela Zavastin
Daniela Zavastin
Igor CRETESCUIgor CRETESCU
Igor CRETESCU
MBMariana Bezdadea
Mariana Bezdadea
MBMilitina Bourceanu
Militina Bourceanu
MDMaria Drăgan
Maria Drăgan
JSJasmina Savic
Jasmina Savic

1 April 2009 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Closed access
Monica BUTNARIUMonica BUTNARIU
Monica BUTNARIU
Ionel I. MangalagiuIonel I. Mangalagiu
Ionel I. Mangalagiu

10 October 2022 in Scientific Reports
Verified
Journal Article
Open access
PDF file
DDDumitrela Diaconu
Dumitrela Diaconu
VAVasilichia Antoci
Vasilichia Antoci
VMVioleta Mangalagiu
Violeta Mangalagiu
DADORINA AMARIUCAI-MANTU
DORINA AMARIUCAI-MANTU
Ionel I. MangalagiuIonel I. Mangalagiu
Ionel I. Mangalagiu
Two new classes of hybrid quinoline–imidazole/benzimidazole derivatives (the hybrid QIBS salts and QIBC cycloadducts) were designed and synthesized to evaluate their anticancer and antimicrobial activity. The strategy adopted for synthesis is straight and efficient, in four steps: N-acylation, N-alkylation, quaternization and a Huisgen 3 + 2 cycloaddition. The in vitro single-dose anticancer assay of forty six hybrid quinoline-benzimidazole compounds reveal that one QIBS salt (11h), has an excellent quasi nonselective activity against all type of cancer cell with an excellent PGI in the area of 90–100% and very good lethality. Three others quinoline–imidazole/benzimidazole hybrids (8h, 12h, 12f) has an excellent selective activity against some cancer cell lines: breast cancer MDA-MB-468 and Leukemia HL-60 TB). The five-dose assay screening confirms that compound 11h possesses excellent anti-proliferative activity, with GI50 in the range of nano-molar, against some cancer cell lines: Leukemia HL-60 TB, Leukemia K-526, Leukemia RPMI-8226, Breast cancer MDA-MB-468, Lung cancer HOP-92 and Ovarian cancer IGROV1. The antibacterial assay indicates that three hybrid QIBS salts (12f, 12c, 12d) have an excellent activity against Gram-negative bacteria E. coli (superior to control Gentamicin) while against Gram-positive bacteria S. aureus only one compound 8i (R2 = -CF3) exhibits a significant activity (superior to control Gentamicin). The MIC assay indicates that two other compounds (11h, 12h) are biologically active to a very low concentration, in the range of nano-molar. We believe that all these excellent assets related to anticancer and antibacterial activities, make from our hybrid quinoline–imidazole/benzimidazole compounds bearing a phenyl group (R2 = –C6H5) in the para (4)-position of the benzoyl moiety a good candidate for future drug developing.

2 June 2016 in Journal of Enzyme Inhibition and Medicinal Chemistry
Verified
Journal Article
Open access
DADORINA AMARIUCAI-MANTU
DORINA AMARIUCAI-MANTU
VAVasilichia Antoci
Vasilichia Antoci
Costel MoldoveanuCostel Moldoveanu
Costel Moldoveanu
Gheorghita ZbanciocGheorghita Zbancioc
Gheorghita Zbancioc
Ionel I. MangalagiuIonel I. Mangalagiu
Ionel I. Mangalagiu
The design, synthesis, structure, and in vitro anticancer and antimycobacterial activity of new hybrid imidazole (benzimidazole)/pyridine (quinoline) derivatives are described. The strategy adopted for synthesis is straight and efficient, involving a three-step setup procedure: N-acylation, N-alkylation, and quaternization of nitrogen heterocycle. The solubility in microbiological medium and anticancer and antimycobacterial activity of a selection of new synthesized compounds were evaluated. The hybrid derivatives have an excellent solubility in microbiological medium, which make them promising from the pharmacological properties point of view. One of the hybrid compounds, 9 (with a benzimidazole and 8-aminoquinoline skeleton), exhibits a very good and selective antitumor activity against Renal Cancer A498 and Breast Cancer MDA-MB-468. Moreover, the anticancer assay suggests that the hybrid Imz (Bimz)/2-AP (8-AQ) compounds present a specific affinity to Renal Cancer A498. Concerning the antimycobacterial activity, only the hybrid compound, 9, has a significant activity. SAR correlations have been performed.

9 January 2020 in Future Medicinal Chemistry
Verified
Journal Article
Open access
VAVasilichia Antoci
Vasilichia Antoci
DCDumitrela Cucu
Dumitrela Cucu
Gheorghita ZbanciocGheorghita Zbancioc
Gheorghita Zbancioc
CMCostel Moldoveanu
Costel Moldoveanu
VMVioleta Mangalagiu
Violeta Mangalagiu
Ionel I. MangalagiuIonel I. Mangalagiu
Ionel I. Mangalagiu
Aim: Over the last decades, few significant achievements have been made in tuberculosis (TB) therapy. As a result, there is an urgent need for new anti-TB drugs. Results: Two new classes of bis-(im...